Gilead Sciences, Inc. (NASDAQ: GILD) — A Fortress HIV Annuity, Re-Rated on a Molecule It Has Barely Begun to Sell

Report date: 2026-06-12 Price reference: ~$125.87 (2026-06-11 close); market cap ~$155B; EV ~$168B; ~1.255B diluted shares; 52-wk $104.46–$157.29

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice and not a recommendation to buy or sell any security. The analysis that follows (sections 1–15) takes no position and carries no price target; valuation there is discussed only as embedded expectations and scenarios.

Verdict — HOLD / quality-franchise-at-a-fair-price. A genuinely great HIV business priced at the top of its own history, with the thing the bull pays for (lenacapavir bridging the Biktarvy cliff) still mostly unproven. Accumulate aggressively only on weakness toward ~$100–110; do not chase strength above ~$145.

Tag: “The best drug franchise in the cohort, bought at the most expensive it has ever been against itself.”

Gilead is the rare large-pharma name where the core asset is unambiguously high-quality: a ~70%-share US HIV franchise with ~87% gross margins, ~$9.5B of fortress free cash flow, ~26% franchise ROIC, a flat share count, and a safe, growing ~2.5% dividend. That is a real Greenwald triple-moat — intangibles + switching costs + R&D scale, reinforced by agency pricing — and it passes both the market-share-stability test (Biktarvy has gained US share every quarter for eight years, now >52%) and the ROIC test. The problem is not the business; it is the price relative to its own past and the timing of two known shocks. The stock has round-tripped from the post-HCV doldrums (~$80 in 2023) to ~$126 on the lenacapavir/PrEP story, leaving it at the 95th percentile of its own decade on P/S and the 88th on P/B even though the absolute P/E (~17x trailing, ~14–15x on clean ex-transaction earnings) still looks moderate. My reverse-DCF says ~$126 embeds only ~3–4% perpetual FCF growth — i.e., the market is paying for “the annuity survives the cliff,” not for a second super-cycle, and is valuing oncology at roughly zero. That is a reasonable thing to pay for, which is exactly why this is a HOLD and not a table-pounding buy or a short: there is no obvious mispricing, and no margin of safety against its own re-rated history.

What keeps me from being more constructive at $126 is that the entire bull case reduces to one unproven question — is lenacapavir additive or merely cannibalizing? — against two dated, asymmetric negatives: Biktarvy (≈49% of product sales) was selected for Medicare price negotiation in January 2026, with a “substantially lower” price effective 2028, five years ahead of its ~2033 patent cliff; and the oncology diversification that is supposed to be the second pillar keeps destroying capital (Forty Seven written off entirely, Immunomedics’ Trodelvy impaired and its EVOKE-03 lung-cancer trial just discontinued in June 2026, Kite cell therapy actually shrinking), even as management spent ~$11.5B of upfront IPR&D on three more deals in 2026 alone. The franchise is getting stronger; the capital deployed to diversify away from it keeps disappointing. Framing: quality-compounder-at-a-fair-price, not contrarian value. Conviction: medium. Flips bullish if HIV total revenue visibly compounds mid-single-digits through the 2028 Medicare hit with Yeztugo/BIC-LEN demonstrably adding net-new (naive) patients and the PrEP category growing double-digits — proving lenacapavir is additive and warranting a durable-annuity re-rate. Flips bearish if the 2028 Biktarvy negotiated cut runs deeper than ~30%, the PrEP switch mix stays ~two-thirds intra-franchise (cannibalization), and another oncology asset fails — at which point the 95th-percentile P/S mean-reverts toward the cliff-pharma multiples of PFE/BMY.

1. Executive Summary

Gilead Sciences is a ~$29.4B-revenue (FY2025), asset-light, very-high-margin biopharmaceutical company whose economic center of gravity is a single, dominant therapeutic franchise: HIV, which contributes ~$20.8B (72%) of product sales and is itself concentrated in one product, Biktarvy ($14.3B, ~49% of all product sales, >52% US treatment share). Around that fortress sit four secondary businesses in varying states of health: a structurally declining liver/HCV book partly re-based by the fast-growing PBC drug Livdelzi; an evaporating COVID tail (Veklury, ~$0.9B and falling); a shrinking cell-therapy unit (Kite — Yescarta/Tecartus, −7% in FY2025); and a genuinely growing but fiercely contested oncology ADC (Trodelvy, +37% YoY in Q1-2026).

The investment is a study in contrasts. The HIV core is one of the best businesses in all of pharma — ~87% non-GAAP gross margin, ~47% operating margin, ~$9.5B of free cash flow on <2% capex intensity, ~26% franchise ROIC, and a moat that is real and financially evidenced. But the topline has been flat for five years (~$27B→$29B, ~1.9% CAGR), with steady HIV growth masked by the runoff of a ~$5B pandemic (Veklury) windfall and the long, self-inflicted decline of the curative HCV annuity. The company is simultaneously fighting two known, dated threats to the franchise: the Inflation Reduction Act, which selected Biktarvy for Medicare price negotiation effective 2028, and the ~2033 Biktarvy patent cliff. Its answer to both is lenacapavir — a first-in-class, long-patent-life capsid inhibitor that is the backbone of up to seven HIV launches by 2033 and of a genuinely new, long-acting prevention (PrEP) category (Yeztugo, twice-yearly injectable, guided to ~$1B in its first full year).

Capital allocation is competent on shareholder returns (a safe, growing ~$4.0B dividend at ~42% of FCF; buybacks that merely offset stock comp) but mixed-to-negative on M&A. Outside the legendary-but-self-cannibalizing Pharmasset/HCV deal, the record is one of overpayment and write-offs (~$10B+ of acquired intangibles impaired this cycle), and the 2026 deal spree (~$11.5B upfront across Arcellx, Ouro, Tubulis) reads as buying growth under cliff pressure. The proxy contains no return-on-capital metric, and the CEO is also Chairman — a governance gap on precisely the decision that matters most.

On valuation, GILD is fair-to-slightly-cheap versus the large-cap-pharma cohort on clean forward earnings (~14–15x) and FCF yield (~6%), but dear versus its own re-rated history (95th-percentile P/S). The price embeds ~3–4% perpetual FCF growth — neither the bull’s super-cycle nor the bear’s naked cliff. The thesis swings almost entirely on one question: does lenacapavir add patients, or just move existing ones to a new molecule at a lower realized price?

2. Business Overview

What Gilead does. Founded 1987, IPO 1992, headquartered in Foster City, California, with ~17,000 employees, Gilead discovers, develops and commercializes prescription medicines for HIV, viral hepatitis, liver disease, oncology and inflammation. It is a research-and-marketing organization wrapped around a small number of blockbuster molecules: it manufactures little physical plant (capex <2% of sales) and earns its returns on intellectual property, clinical-development capability and a global commercial infrastructure. Revenue is overwhelmingly US-weighted and concentrated in a handful of branded products.

Revenue segmentation (FY2025 product sales $28.9B; total revenue $29.4B incl. $0.5B royalty/contract). (FACT — FY2025 10-K MD&A product table.)

End markets & customers. Gilead sells to specialty distributors, pharmacies, hospitals, government programs (Medicaid, Medicare Part D, the VA, 340B covered entities) and public-health buyers (e.g., Ryan White). Demand is disease-driven and largely non-cyclical; pricing is an agency relationship — physicians prescribe, payers reimburse, patients bear the clinical risk of switching — which historically conferred durable pricing power now being partially capped by the IRA (Section 3).

How it makes money, and how durable each dollar is. (INTERPRETATION.) The quality of Gilead’s revenue varies enormously by line:

• HIV treatment (~$17B+) is the crown jewel: chronic, lifelong daily therapy where virally-suppressed patients almost never switch (rebound/resistance risk). The most durable, recurring, moat-protected revenue in the company.
• HIV prevention / PrEP (Descovy + Yeztugo, ~$3.5B and growing) is recurring but more elastic (adherence-driven) and is the genuine net-new growth category.
• HCV (Epclusa, Harvoni) is the curative-drug paradox in action: the medicine cures in 8–12 weeks, so every sale removes a future customer. This is the self-liquidating annuity that sank the 2015–2020 Gilead story and is now a small residual.
• Veklury is an episodic pandemic tail, nearly exhausted.
• Cell therapy (Kite) is one-and-done and, critically, declining.
• Trodelvy is recurring-until-progression but in a hyper-competitive class.

Verdict: A high-margin, cash-generative franchise whose durable core (HIV treatment + the PrEP build, ~$20B+) is excellent, but whose “diversification” lines are mostly declining (HCV, Veklury, Kite) or unproven (Trodelvy ex-breast, anito-cel). The single most important business fact is concentration: one product (Biktarvy) is half of sales, and one franchise (HIV) is ~72%.

3. Industry Dynamics

HIV therapeutics — a structurally attractive oligopoly. The global HIV market is ~$30B+, anchored by ~1.2–1.3M people living with HIV in the US (a chronic, lifelong, reimbursed population) plus a growing prevention pool. Barriers to entry are formidable: a new regimen requires ~$1B+ and roughly a decade of trials (lenacapavir took ~17 years concept-to-approval), the efficacy/safety/resistance bar set by existing regimens is extremely high, and demand is non-cyclical and guideline-driven. The competitive set is concentrated: Gilead (dominant — >50% US treatment share via Biktarvy, ~70%+ of the US HIV franchise including PrEP); ViiV Healthcare (majority GSK, with Pfizer/Shionogi minorities) holding the leading long-acting injectables (Cabenuva for treatment, Apretude for every-two-month PrEP) and the dolutegravir family; and Merck as a #3-and-pipeline threat — a “frenemy” that is partnered with Gilead on the once-weekly oral islatravir/lenacapavir regimen yet also fields its own competing capsid and doravirine programs. On a Greenwald industry test, HIV passes decisively: high barriers, few credible players, stable-to-growing demand, agency pricing. (FACT/INTERPRETATION — 10-K; Bernstein SD Conf 2026-05-28; Q1-26 call.)

The IRA is the central structural overhang — and it is now concrete, not theoretical. (FACT — FY2025 10-K.) In January 2026, HHS selected Biktarvy for Medicare drug-price negotiation, with a negotiated Maximum Fair Price effective 2028. Management states the negotiated price will be “substantially lower” than the current price and will also raise Medicaid rebates and lower 340B ceiling prices — i.e., the hit cascades across channels. This lands on Gilead’s single most important product, on its highest-margin channel. Layered on top: FY2025 already absorbed a ~$1.2B Medicare Part D redesign headwind (the IRA catastrophic-cap restructuring), and a December 2025 drug-pricing agreement with the US government to lower Medicaid pricing on some products, plus proposed ACA changes, together create a ~2% growth headwind to HIV in 2026 (quantified by management; absent it, base-business growth would be ~7–8% rather than the 5–6% guided). The IRA is a genuine, recurring, asymmetric tax on the pricing-power pillar of the moat — it does not break the franchise, but it caps it on the products that matter most, on a rolling forward schedule (Descovy, Genvoya and Odefsey are plausible future selection candidates).

Oncology — the opposite of HIV. The ADC and cell-therapy spaces Gilead is pivoting into are crowded, fast-moving, capital-intensive and low-barrier on durable advantage. In ADCs, AstraZeneca/Daiichi Sankyo (Enhertu; Datroway, which carries a near-term TNBC PDUFA directly threatening Trodelvy), Merck and Pfizer/Seagen are all racing. In myeloma CAR-T, J&J/Legend (Carvykti) and BMS (Abecma) are entrenched incumbents that Gilead’s anito-cel must displace. A PD-1/VEGF bispecific wave (Summit/Akeso) is reshaping solid-tumor standard-of-care beneath Trodelvy. In Marathon capital-cycle terms, this is a “capital-pouring-in, returns-competed-away” zone — heavy R&D and M&A, no supply discipline, rapid obsolescence.

The capital-cycle read. (INTERPRETATION — Marathon lens.) HIV has a favorable supply side (consolidated, disciplined, high-barrier, no new capacity), which justifies premium economics and suspends mean-reversion. Oncology has an unfavorable supply side (capital flooding in through biotech M&A — Gilead itself put ~$11.5B of upfronts into the space in a single quarter). Gilead is redeploying cash from a favorable-supply business into an unfavorable-supply one — the classic asset-growth-anomaly warning that predicts low forward returns on the incremental oncology dollars.

Verdict: HIV/specialty virology is a structurally good industry (oligopoly, high barriers, non-cyclical demand, agency pricing) — but with a material and worsening regulatory tax. Oncology (ADC + cell therapy) is a structurally poor, hyper-competitive industry where Gilead has no structural edge. ~83% of the revenue base sits in good industries (HIV + liver); incremental capital is deliberately flowing into bad ones.

4. Competitive Position

The HIV moat is a genuine Greenwald “triple” reinforced by agency pricing — the strongest configuration, and it is financially evidenced. (INTERPRETATION, grounded in the FACTs below.)

1. Intangibles / proprietary technology (primary). Composition-of-matter and formulation patents on the TAF backbone, bictegravir, and lenacapavir. Patents are Greenwald’s most transient advantage — but Gilead runs a patent-ladder / evergreening machine: each new best-in-class regimen (TAF → Biktarvy → the lenacapavir era) re-starts the exclusivity clock before the prior one cliffs, and the bar is now so high that competition has shifted from efficacy to dosing-interval convenience, where Gilead also leads.
2. Switching costs / customer captivity (demand). Virally-suppressed patients rarely switch (clinical risk), and treatment guidelines (DHHS, IAS-USA) entrench Biktarvy first-line for both naive and switch patients. The ~20% of patients who do switch each year are mostly captured internally by Gilead’s own newer products.
3. Economies of scale + R&D scale (supply). Gilead runs the deepest HIV R&D engine in the world (60 abstracts at CROI 2026; a seven-launch-by-2033 HIV pipeline). Fixed R&D and commercial infrastructure amortized over >50% share is a per-unit cost/innovation advantage rivals cannot match — the Greenwald economies-of-scale-plus-captivity combination, the most durable advantage there is.

The tests confirm it. (FACT.) On the market-share-stability test, Biktarvy’s US treatment share has risen year-over-year every quarter since its 2018 launch, now >52%; total HIV grew $18.2B → $19.6B → $20.8B across 2023–25. Share that is stable-to-rising over 5–8 years is the textbook signature of a real, durable moat. On the ROIC test, the franchise earns ~87% gross margin, ~47% operating margin and well above the 15–25% bar (capex <2% of sales). The moat is real precisely where the profitability is real: HIV.

Pressure-test: durable to 2040, or a patent cliff in disguise? (INTERPRETATION — the central debate.) The bear “cliff-in-disguise” view: Biktarvy is ~49% of product sales facing both Medicare negotiation (2028) and a ~2033 COM cliff; if lenacapavir regimens do not migrate that revenue in time, this is an HCV-style collapse. The bull “engineered-transition” view, which the evidence favors: (a) management guides to “no major LOE until 2036,” because generics cannot fully erode while lenacapavir patents stand; (b) lenacapavir is a new mechanism (first-in-class capsid inhibitor) with its own long patent life and is the backbone of seven potential launches; © Gilead has executed exactly this kind of transition once before (TAF → Biktarvy), capturing its own switch market; and (d) PrEP is genuine net-new growth (Yeztugo +72% sequentially, ~$1B FY26 guide, with only ~0.5M of a ~2.2M-eligible pool currently treated). The risk is timing and IRA depth, not the existence of the moat. This is not a naked cliff like HCV — HCV cured its own customers; HIV is chronic and Gilead owns the next-generation molecule.

Oncology — little or no durable moat. (INTERPRETATION.) Kite/cell therapy has no moat: revenue is declining under in-class and out-of-class (bispecific) competition, and its only edge — manufacturing/vein-to-vein logistics — is operational effectiveness, not a Greenwald barrier. Trodelvy is a real, differentiated product (leading 2L mTNBC ADC, NCCN Category 1) but faces a direct PDUFA threat from AZ/Daiichi’s Datroway and the broader ADC arms race; it is patent-protected and growing, but Gilead is sub-scale against the AZ/Daiichi scale leaders. Anito-cel (just acquired via Arcellx) is a potential best-in-disease BCMA CAR-T with a differentiated clean-neurotoxicity profile, but it must displace entrenched Carvykti/Abecma in a market where Gilead’s own Kite franchise is shrinking. Per Greenwald, differentiation without barriers earns average returns; per Marathon, asset growth into a competed-away space predicts low forward returns.

Verdict: A durable, multi-source competitive advantage that is real and financially evidenced in HIV — passing both the share-stability and ROIC tests — durable past the 2033 Biktarvy cliff conditional on lenacapavir execution, and taxed (not broken) by the IRA. In oncology, no durable moat: differentiated products in hostile, competed-away industries, acquired at high prices and value-dilutive to date. The investment is a fortress HIV cash-cow re-rated on genuine lenacapavir/PrEP optionality, partially funding an unproven low-moat oncology pivot.

5. Growth History and Forward Opportunities

History: a flat topline hiding a violent mix shift. (FACT — FY2025 10-K.) Total revenue ran $27.3B (2021) → $27.3B (2022) → $27.1B (2023) → $28.8B (2024) → $29.4B (2025): ~1.9% CAGR, essentially flat. That flat line is the algebraic sum of three offsetting tides:

1. HIV grew steadily — ~$16–17B (2021–22) → $18.2B (2023) → $19.6B (2024, +8%) → $20.8B (2025, +6%), with Biktarvy compounding $11.85B → $13.42B → $14.33B. This is the durable engine.
2. HCV/Veklury collapsed — Veklury fell from a ~$5.6B pandemic peak (2021) to $0.91B (2025), a ~$5B tailwind that fully reversed and masked the HIV growth; HCV self-liquidated to a small residual.
3. Oncology stagnated — cell therapy −7% in FY2025 (and declining), Trodelvy +6% (accelerating later). Net oncology −2%.

The honest read: stripping the Veklury runoff, the base business compounded mid-single-digits. But the quality of historical growth is narrow — almost entirely one franchise (HIV), increasingly one product (Biktarvy). A decade of diversification spend (Kite, Immunomedics, CymaBay) has not yet produced a second growth pillar; only Trodelvy and Livdelzi are genuinely additive.

Forward drivers. (FACT on guidance/pipeline; INTERPRETATION on sizing.)

• Yeztugo / lenacapavir PrEP — the new-category bet. FY26 guidance raised to ~$1B (from $800M); Q1-26 sales +72% sequentially; US PrEP business +87% YoY; 95% payer coverage, 95% of those at $0 copay. Twice-yearly subcutaneous dosing leapfrogs ViiV’s every-two-month Apretude and daily orals. The TAM is real — CDC’s PrEP-eligible estimate was raised ~1.2M → ~2.2M, with only ~0.5M currently treated and management targeting >1M by mid-2030s. The crucial caveat: the Q1-26 switch mix split roughly one-third / one-third / one-third across other long-acting injectables / generic Truvada / Gilead’s own Descovy — meaning ~two-thirds of early Yeztugo volume is intra-franchise or low-margin-generic conversion, not net-new. Whether the naive (net-new) share grows is the whole ballgame.
• Seven HIV launches by 2033 — the engineered Biktarvy transition. BIC/LEN (oral once-daily bictegravir+lenacapavir), the designated Biktarvy successor that re-starts the patent clock, has a PDUFA in August 2026; once-weekly oral islatravir/lenacapavir (Merck partnership) read out positive Phase 3 in June 2026; GS-3242/lenacapavir twice-yearly injectable and once-yearly IM lenacapavir (targeted ~2028) extend the dosing-interval ladder.
• Oncology / other. Trodelvy has 1L mTNBC decisions in 2H-2026 (a real expansion) — but the EVOKE-03 lung-cancer trial failed in June 2026, removing the NSCLC leg, and Datroway is a near-term TNBC competitor. Anito-cel (Arcellx) has a December 2026 PDUFA, early-2027 launch, and a ~$3.5B 4L+ myeloma TAM. Livdelzi (PBC) is small but compounding fast (+200% YoY). Inflammation (gamgertamig and ~10 clinical assets) is pure optionality with no near-term revenue.

Can lenacapavir offset the 2028 Medicare hit + 2033 cliff? (INTERPRETATION.) The entire bull thesis reduces to this. Gilead must replace a meaningful slice of a ~$14B product as Medicare cuts its realized price from 2028 and generics erode the residual from 2033–34. The designated replacements are LEN-based PrEP (scaling from $1B toward multi-billions), BIC/LEN (capturing Biktarvy’s own switch base), and LEN injectables. The TAF→Biktarvy precedent shows Gilead can execute a self-cannibalizing franchise renewal; the risk is timing and IRA depth, not whether the molecule exists.

Verdict: Mixed-quality growth. The HIV/PrEP engine is high-quality (durable, ~87% gross margin, recurring, moat-protected, genuinely net-new PrEP category) and is the real reason to own GILD. The oncology growth is low-quality (crowded, low-moat, capital-destructive — EVOKE-03 failed, Kite shrinking). Consolidated forward growth is plausibly mid-single-digit base business through the late 2020s, but it is back-end-loaded and contingent on the lenacapavir transition clearing the 2028 negotiation and 2033 cliff. This is not a secular grower; it is a fortress annuity attempting one more franchise-renewal cycle.

6. Financial Quality

Margins and the structure of profit. (FACT — FY2025 10-K.) GAAP product gross margin is ~78% (COGS includes ~half manufacturing, ~half acquired-intangible amortization and royalties); non-GAAP product gross margin is ~87% and rose ~2 points on the expiry of a long-standing TAF royalty. R&D ex-acquired-IPR&D is ~$5.8B (~20% of revenue, roughly flat) — modest for big pharma, because Gilead supplements thin internal R&D by buying pipeline (more on this in §7). SG&A is ~$5.8B. Non-GAAP operating margin is ~47%, top-quartile. The base HIV business converts revenue to cash about as efficiently as any drug franchise in the world.

The central quality-of-earnings flag: IPR&D makes GAAP earnings non-representative. (FACT.) GAAP operating income swings violently — $7.3B (2022) → $7.6B (2023) → $1.66B (2024) → $10.0B (2025) — and GAAP net income with it: $6.2B (2021), $4.6B (2022), $5.7B (2023), $0.48B (2024), $8.5B (2025). The driver is two M&A P&L lines under asset-acquisition accounting, which expenses deal upfronts immediately:

The 2024 collapse was $3.8B of CymaBay IPR&D plus $4.2B of Immunomedics/Trodelvy impairment. For 2026, the ~$11.5B of upfronts (Arcellx + Ouro + Tubulis) is guided to produce a non-GAAP loss per share of $(1.05)–$(0.65) and an effective tax rate of 140–190% (the deal costs are largely non-deductible) — even as ex-transaction non-GAAP EPS holds at $8.45–$8.85. GAAP EPS is uninvestable as a signal here; the correct lens is normalized/owner earnings and FCF.

But non-GAAP is not clean either. (INTERPRETATION — the honest QoE point.) Company non-GAAP strips IPR&D, impairments and acquired-intangible amortization — i.e., the recurring cash cost of a serial-acquirer model that does ~$11.5B of deals in a single year. Treating those as “non-operating” overstates owner earnings. Triangulating: add back 2025’s M&A noise (~$1.6B pretax, ~$1.3B after-tax) to GAAP NI gives ~$9.8B normalized net; the FY26 ex-transaction non-GAAP guide implies ~$10.6–11.1B; the honest owner-earnings number sits between and below the non-GAAP headline, ~$8.5–9.0B normalized net income, with ~$9.5B FCF as the cleanest single figure (OCF ~$10.0B − capex ~$0.56B).

Balance sheet — conservative. (FACT.) Gross debt ~$24.9B (senior unsecured notes $23.8B + a $1.1B royalty-monetization liability), against ~$10.6B of cash and marketable securities — net debt ~$14.3B, roughly 1.0x normalized EBITDA, well-laddered (no maturity wall; ~$17.5B is “thereafter”). This is not a balance-sheet risk. Goodwill is flat at ~$8.3B, but ex-goodwill intangibles have fallen fast — $33.5B (2021) → $17.0B (2025) — and indefinite-lived IPR&D intangibles collapsed $15.9B → $2.3B. That decline is partly amortization but heavily impairment: the accounting is honest, and what it honestly documents is ~$10B+ of acquired intangibles written off this cycle. Conservative reporting of capital destruction, not its avoidance.

Cash conversion, ROIC, ROE. (FACT + computed.) OCF has held a durable $10.0–10.8B in recent years and exceeds GAAP NI in distorted years (2024 OCF $10.8B vs NI $0.48B) — confirming GAAP NI ≠ economic cash. SBC is modest and rising (~$0.9B, ~3% of revenue — low for biopharma). Diluted shares are flat (~1,255M); buybacks merely offset SBC. ROE looks spectacular (~37% GAAP, ~43% normalized) but is flattered by a buyback-shrunk, impairment-eroded equity base (book only ~$18/sh, hence the meaningless 6.7x P/B — equity is small precisely because billions of acquired assets were written off through it). ROIC on a normalized basis (~$9.5B NOPAT over ~$37B invested capital including goodwill) is ~26% — but that is after the impaired intangibles were removed from the denominator; adding back the cumulative write-offs, the incremental ROIC on the M&A spend is materially lower. The base HIV business earns superb returns; the acquisitions have destroyed capital.

Verdict: Do economics improve with scale? For the core HIV franchise, emphatically yes (~87% non-GAAP GM, ~26% ROIC, ~100%+ cash conversion, flat shares). For the consolidated enterprise, no — a decade of acquisitions (cell therapy now declining, ~$10B+ written off) has consumed HIV cash flows at sub-cost-of-capital returns. Gilead is a superb single-franchise cash annuity wrapped in a value-destructive M&A machine. The right earning-power anchor is ~$8.5–9.0B normalized net / ~$9.5B FCF, not the ~$10.5–11B non-GAAP headline.

7. Capital Allocation

Philosophy: return ~60% of FCF, recycle the rest (plus balance-sheet capacity) into pipeline M&A. (FACT — Q1-26 call; 10-K; 2026 proxy.) In Q1-2026 Gilead returned >$1.4B to shareholders (~$1.0B dividend + >$0.4B buyback), ~60% of FCF.

• Dividend — exemplary. Grew from $3.71B (2022) to ~$4.0B (2025); ~$3.16/share, ~2.5% yield, raised every year since initiation in 2015. At ~$4.0B against ~$9.5B FCF (~42% payout) it is safe and well-covered even through GAAP-loss years, because the losses are non-cash IPR&D while OCF holds ~$10B. This is the genuine shareholder value transfer.
• Buyback — honest but unremarkable. $1.4B (2022), $1.0B (2023), $1.15B (2024), $1.9B (2025), ~$0.4B in Q1-26 — enough to sterilize ~$0.9B/yr of SBC and hold the share count flat, but not a valuation-sensitive lever.
• R&D intensity is modest (~$5.8B, <20% of sales), because Gilead outsources a chunk of R&D to M&A, run through the IPR&D line.

M&A track record — scored honestly. (FACT on price/date; INTERPRETATION on grade.)

The 2026 spree totals ~$11.5B of upfront IPR&D — roughly one full year of normalized net income spent in one year, producing a guided GAAP loss. Cumulatively, ex-goodwill intangibles fell from $33.5B (2021) to $17.0B (2025), with ~$10B+ written off. (INTERPRETATION — Marathon lens: Gilead is deploying cash at the top of an oncology/cell-therapy/I&I capital cycle the whole industry is crowding into, selling out of a high-moat supply-constrained business to buy competed, capital-hungry modalities with no demonstrated moat and a loss record — the asset-growth anomaly flashing value-erosion. Mitigant: upfronts are expensed immediately with prompt impairments, and on the Q1-26 call management signaled it is “less likely to pursue more sizable M&A this year,” a possible top-of-cycle discipline tell.)

Incentive alignment — a real governance gap. (FACT — 2026 DEF 14A.) The annual cash incentive is 60% financial (Adjusted Net Product Revenue + Adjusted Operating Income; the financial weight was raised from 50% in 2025) + 40% strategic; long-term incentives are 50% performance shares (3-yr relative TSR + a newly added multi-year adjusted-EPS-growth metric), 25% options, 25% RSUs. There is no return-on-capital metric anywhere in the proxy — zero mentions of ROIC/ROTC/ROE. For a company whose central question is whether ~$11.5B/yr of M&A earns its cost of capital, executives are paid on revenue, operating income, EPS growth and TSR — all of which a serial acquirer can hit by buying revenue regardless of value created. CEO Daniel O’Day (Chairman & CEO since 2019) earned ~$28.4M in 2025 SCT total (base <7% of total — good alignment on form, wrong metrics). Say-on-pay support is ~91% (adequate, not strong), and a stockholder proposal for an Independent Board Chair recurs (O’Day holds the combined role) — investor concern aimed precisely at oversight of the capital allocation flagged here.

Insider signal — neutral. (FACT — Form 4 sweep, 120 of 328 recent filings.) Zero open-market purchases by any individual insider (the only “P” codes are Gilead-the-corporation buying stakes in collaboration partners — Arcus, Xilio, Assembly). Of 52 insider sale filings, 51 carry explicit Rule 10b5-1 footnotes — routine, pre-scheduled diversification by O’Day, CFO Dickinson, CCO Mercier and others. No conviction buying, no red-flag selling. No information content either way.

Verdict: Mixed-to-negative on M&A, positive on shareholder returns. The dividend is exemplary; the buyback is honest. But the M&A machine — outside the wasting-asset Pharmasset win — is a record of overpayment and write-offs, and the 2024–26 spree reads as buying growth under cliff pressure. Management returns the cash-cow’s output competently but has not shown it can convert M&A into durable franchise value beyond HIV; the missing ROIC metric and combined Chair/CEO compound the concern. Capital allocation is a thesis risk, not a strength.

8. Changes and Headwinds — Last Two Years

(FACT timeline — 8-Ks, transcripts, AZI news feed.)

• Feb 2024: CymaBay (~$4.3B, Livdelzi/PBC); $3.8B IPR&D + $4.2B Trodelvy impairment crush FY24 GAAP NI to $0.48B.
• 2025 H2: Yeztugo (lenacapavir PrEP) launch — FY26 guide later raised to ~$1B, a potential first-year blockbuster; total-HIV growth guide raised 6%→8%. (POSITIVE — the optionality underwriting the bull case.)
• Jan 2026: Biktarvy selected for Medicare price negotiation, negotiated price effective 2028 — a structural pricing headwind on the ~49%-of-sales flagship, ahead of its 2033 cliff. (NEGATIVE, slow.)
• Dec 2025: drug-pricing agreement with the US government (lower Medicaid pricing) + proposed ACA changes → ~2% growth headwind in 2026. (NEGATIVE, quantified, manageable.)
• 2026-03-31: Galapagos collaboration restructured around gamgertamig (BCMAxCD3 T-cell engager); ~$1.675B upfront split 50/50 + up to $500M milestones.
• 2026-04-28: Arcellx closed (~$7.8B, anito-cel CAR-T myeloma).
• Q2-2026: Ouro + Tubulis expected to close; collectively the ~$11.5B IPR&D that drives the FY26 GAAP loss.
• 2026-06-08 (POSITIVE): islatravir/lenacapavir once-weekly oral HIV (with Merck) Phase 3 positive — extends lenacapavir into weekly oral dosing, reinforcing the post-Biktarvy bridge.
• 2026-06-08/09 (NEGATIVE): EVOKE-03 (Trodelvy+Keytruda, 1L NSCLC) discontinued for futility; the stock traded lower. A meaningful Trodelvy label-expansion indication lost — directly undercutting the $21B Immunomedics thesis.
• Ahead (thesis-critical): BIC/LEN PDUFA in August 2026 — the next-gen HIV regimen meant to extend the franchise past the Biktarvy cliff.

Verdict: Net mixed, tilting to a more-fragile thesis. The HIV/lenacapavir engine strengthened in real time (Yeztugo blockbuster trajectory, once-weekly oral Phase 3 win, BIC/LEN pending) — the high-moat core is executing. But the oncology/M&A leg weakened (EVOKE-03 failure on the $21B asset; ~$11.5B fresh unproven IPR&D; cell therapy declining), and pricing policy is a slow structural drag. The franchise the moat rests on is getting stronger; the capital spent to diversify away from it keeps disappointing.

9. Risk Analysis

The dominant risks are structural and dated (Biktarvy concentration + the 2028 Medicare cut + the 2033 cliff) rather than acute. A catastrophic permanent loss is highly unlikely given the cash generation and balance sheet; the realistic bear outcome is multi-year stagnation and a de-rating, not impairment.

10. Valuation Discussion (Embedded Expectations)

Starting multiples (2026-06-11/12). (FACT.) At ~$125.87, market cap ~$155B, EV ~$168B, ~1.255B shares, net debt ~$14.3B: TTM P/E ~17.0x; clean forward P/E ~14.2–14.9x on ex-transaction non-GAAP EPS of $8.45–$8.85 (the GAAP-loss guide is meaningless); EV/EBITDA ~11.4x; P/S ~5.2x; P/B ~6.7x (book impaired/meaningless); dividend ~2.5% at ~40% FCF payout; FCF ~$9.5B → FCF yield ~6.1% on market cap. Critically, on its own ~10-year history the stock sits at the 53rd percentile on P/E but the 95th on P/S and 88th on P/B — it has re-rated up from the post-HCV doldrums (~$80 in 2023) on the lenacapavir/PrEP story. The “cheap on P/E” read is an absolute-level illusion; against itself, GILD is near the top of its decade range.

Embedded-expectations / reverse-DCF. (INTERPRETATION.) Anchoring on owner FCF ~$9.5B (the cleanest figure, below the non-GAAP $10.5–11B that strips recurring M&A cash cost), a simple FCF-perpetuity at a 10% equity discount rate implies ~3–4% perpetual FCF growth embedded at ~$126 (at a more typical ~8.5–9% pharma COE, ~2.5–3.0%). In words: the market is underwriting that lenacapavir successfully offsets the Biktarvy Medicare hit and the 2033 cliff and the franchise grows roughly with healthcare inflation in perpetuity, with oncology valued at ~zero-to-modest. This is not an aggressive embedded number — it is well below the 6–8% base-business growth the company would post absent policy. It prices a durable-but-low-growth annuity that survives the cliff. Neither the bull’s “second super-cycle” nor the bear’s “naked cliff / oncology black hole” is in the price.

Scenarios (5-yr, to ~2030; ex-transaction non-GAAP EPS basis; ASSUMPTION).

The asymmetry is roughly balanced-to-slightly-favorable: the base case sits modestly above spot plus the ~2.5% yield, while the bull and bear are roughly symmetric in magnitude — but the bear’s de-rate is the sharper, more probable risk given the 95th-percentile starting P/S.

Peer comps (recomputed). (FACT + INTERPRETATION.) Across the large-cap-pharma cohort, GILD’s clean forward P/E (~14–15x) and EV/EBITDA (~11.4x) sit mid-pack — richer than the cliff/value names (PFE ~9x, BMY ~9x), in line with ABBV/MRK (~13x), below the diversified premium of JNJ (~19x) and AMGN (~15x); its ~6% FCF yield screens attractively. Notably, GILD trades closer to the cliff-discount group on P/E despite owning a higher-quality core franchise — i.e., the market already applies a partial cliff discount for the Biktarvy 2028/2033 overhang.

Verdict: GILD at ~$126 is fairly valued — cheap-to-fair versus the cohort on clean forward earnings and FCF yield, but dear versus its own re-rated history. The price embeds ~3–4% perpetual FCF growth (“annuity survives the cliff,” oncology ~zero). The re-rate has largely happened; the lenacapavir optionality is substantially priced in, leaving little margin of safety against itself. No price target.

11. Variant Perception

Consensus. Sell-side is buy-tilted (~$158 mean target, ~4.13/5 rating); short interest is only ~1.9% of float — not a crowded short. The Street view: a high-quality HIV cash-cow where lenacapavir/PrEP de-risks the cliff, fortress FCF and a growing dividend back a quality-at-a-reasonable-price defensive grower. The ~$80→~$126 re-rate reflects the Street buying that story.

Strongest bull case. Lenacapavir is a second HIV super-cycle, not merely a Biktarvy patch: a first-in-class capsid inhibitor with late-2030s/2040s patents, the backbone of seven launches spanning treatment and a genuinely net-new long-acting prevention category (Yeztugo ~$1B in year one; PrEP TAM 0.5M→2.2M eligible). The franchise extends durably to ~2040 (“no major LOE until 2036”). On a fortress of ~87% gross margin, ~$9.5B FCF, ~26% franchise ROIC, a flat share count and a 2.5% growing dividend, if the market comes to see HIV as a durable consumer-staple-like annuity, GILD re-rates from ~14x toward ~17–18x. Trodelvy (1L), anito-cel and Livdelzi are free options on top.

Strongest bear case. Biktarvy is a ~49%-of-sales single point of failure facing a double hit — Medicare negotiation (2028) and its ~2033 cliff. Lenacapavir largely cannibalizes (switch mix ~two-thirds from existing Gilead/generic users) rather than adds, so the transition shuffles revenue at a lower realized price rather than growing it. Oncology is a serial capital-destroyer (Kite shrinking, Forty Seven written off, Immunomedics impaired, EVOKE-03 just failed), and the 2026 ~$11.5B M&A spree masks organic stagnation (flat 5-yr topline). The re-rate to the 95th-percentile P/S leaves no margin of safety; on owner earnings (~$9.5B FCF, below non-GAAP) the “cheap 14x” is really ~16–17x. A taxed, concentrated annuity dressed up as a growth re-rating.

The assumptions that matter most, and what falsifies each side.

1. Lenacapavir additive vs. cannibalizing (the dominant swing factor). Falsifies bull: BIC/LEN + LEN-injectable revenue fails to ramp 2027–29; total HIV revenue flat/declines through the 2028 negotiation; Yeztugo switch-mix stays ~⅔ intra-franchise. Falsifies bear: HIV total revenue keeps compounding MSD through 2028–30 with LEN regimens visibly adding net-new patients.
2. Depth of the 2028 Biktarvy Medicare cut + breadth of future IRA selection. Falsifies bull: negotiated price + Medicaid/340B knock-on cuts Biktarvy realized price >25–30%, with more HIV products selected. Falsifies bear: the cut is modest/limited-mix and no further core-HIV products are selected near-term.
3. PrEP TAM is real net-new demand (0.5M→1M+) vs. a re-shuffle. Falsifies bull: PrEP market growth decelerates from ~14%; Yeztugo persistency/naive share disappoint. Falsifies bear: the PrEP-treated population visibly steps up and Yeztugo sustains a multi-billion trajectory.
4. Oncology ever earns its cost of capital (or is correctly valued at ~zero). Falsifies bull-as-upside: more EVOKE-style failures / Trodelvy share loss to Datroway / anito-cel disappoints. Falsifies bear-as-black-hole: Trodelvy 1L + anito-cel turn oncology into a genuine second pillar with positive incremental ROIC.
5. The multiple: durable-annuity re-rate vs. cliff-discount de-rate.

Verdict: Consensus is constructively neutral-to-bullish and un-crowded. The variant perception cuts both ways — the bull variant is a durable franchise the market still prices with a partial cliff discount (re-rate option); the bear variant is that the lenacapavir story is already priced at the 95th-percentile P/S while the cliff/IRA/oncology risks are real and front-loaded into 2028. The single dominant swing factor is #1.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the magnitude of the 2028 Biktarvy Medicare negotiated-price cut, and what share of Biktarvy revenue is Medicare-exposed? Management gives no number; this is central to the 2028→2033 bridge.
2. What is the net-new vs. switch split of Yeztugo/PrEP demand? The single most thesis-critical unknown — the difference between additive growth and a lower-price reshuffle.
3. What are lenacapavir’s exact composition-of-matter/formulation patent expiry dates? “No major LOE until 2036” is management framing; the post-2033 durability hinges on Orange Book specifics.
4. Will anito-cel (Arcellx) or gamgertamig (Ouro) break the pattern of value-dilutive oncology M&A? No clinical/commercial readout yet; decides whether the 2026 spree was renewal or destruction.
5. How much of the $21B Immunomedics/Trodelvy thesis survives EVOKE-03? The mTNBC franchise plus remaining indications versus the lost lung-cancer leg.

14. What Must Be True

For the bull case to be right:

• Lenacapavir-based regimens (BIC/LEN, once-weekly oral, injectables) must ramp fast enough to hold total HIV revenue growing through the 2028 Medicare cut and the 2033 cliff, with visible net-new (naive) PrEP patients — not just intra-franchise switching.
• Falsification test: if, by FY2028, total HIV revenue is flat-to-down and the Yeztugo/PrEP switch mix remains ~two-thirds intra-franchise with no acceleration in naive starts, the engineered transition is failing and the bull case is broken.

For the bear case to be right:

• The 2028 Biktarvy Medicare cut must be deep (>~30% realized-price erosion on the Medicare book), lenacapavir must prove net-cannibalizing, and oncology must keep destroying capital — collapsing the franchise toward a cliff-pharma multiple.
• Falsification test: if HIV total revenue compounds mid-single-digits through 2028–2030, PrEP grows double-digits with rising naive share, and Trodelvy 1L / anito-cel launch into genuine second-pillar revenue with positive incremental ROIC, the bear “stagnating taxed annuity” thesis is broken and a durable-annuity re-rate is warranted.

The analysis above (sections 1–14) takes no investment position and contains no price target; valuation is discussed solely as embedded expectations and scenarios. The single, clearly-labeled exception is the Claude's Take block at the top, which is the author’s own subjective view.

15. Source Appendix

The full enumerated source list follows in Appendix B below.

APPENDIX A — Standard Diligence Questionnaire

Gilead Sciences, Inc. (NASDAQ: GILD) — as of 2026-06-12

Supplemental to the research memo. Answers are grounded in the underlying evidence; Fact / Interpretation / Assumption labels applied where it matters.

General

What thoughtful questions have other investors asked about this company? The dominant investor debate is binary and singular: is lenacapavir additive or cannibalizing? Sub-questions: How deep is the 2028 Biktarvy Medicare cut, and will more HIV products be selected? Is the PrEP TAM real net-new demand or a reshuffle of existing users? Will any of the oncology M&A (Kite, Immunomedics, Arcellx) ever earn its cost of capital, or should oncology be valued at zero? Is the ~$80→~$126 re-rate justified, or has the market already priced the lenacapavir optionality at the 95th-percentile P/S? Is the dividend safe through a GAAP-loss year (yes — the loss is non-cash IPR&D)?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? (Interpretation.) Neither — pharma earnings are disease-driven, not macro-cyclical. But GILD is at a mix inflection: the ~$5B Veklury (COVID) windfall has fully reversed (a drag now nearly exhausted), HCV has bottomed, and the franchise is entering the lenacapavir-transition phase ahead of the 2028 Medicare cut and 2033 cliff. Normalized earning power (~$8.5–9.0B net / ~$9.5B FCF) is a fair mid-cycle read.

Driven by the external environment or internal actions? Predominantly internal (product launches, pricing, R&D/M&A), with a growing external overlay from IRA/Medicaid/ACA policy (~2% headwind in 2026, rising).

How stable are revenues? Very stable in aggregate (chronic HIV treatment is sticky, recurring revenue), but concentrated (Biktarvy ~49% of product sales) and facing two dated step-downs (2028 negotiation, 2033 cliff).

Outlook for products/services? HIV treatment durable; PrEP a genuine growth category; HCV/Veklury declining; cell therapy declining; Trodelvy growing but contested (EVOKE-03 NSCLC failed); Livdelzi small/fast-growing.

How big will this market be? Global HIV ~$30B+ and growing modestly; US PrEP-eligible pool ~2.2M (only ~0.5M treated) — the principal expansion vector. Oncology TAMs are large but hyper-competitive.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? HIV: stable oligopoly, but ViiV (long-acting injectables) and Merck (capsid/islatravir) are pushing on dosing-interval convenience; the IRA adds a regulatory competitor (government as price-setter). Oncology: intensely and increasingly competitive.

How profitable is the business (ROIC, ROE)? (Fact + computed.) Franchise (HIV): ~87% non-GAAP gross margin, ~47% operating margin, ~26% normalized ROIC, ~100%+ cash conversion. ROE ~37% GAAP/~43% normalized but flattered by an impairment-eroded, buyback-shrunk equity base (~$18/sh book). Consolidated incremental ROIC on M&A is well below cost of capital.

How profitable is the industry — competitors, barriers? HIV is highly profitable with formidable barriers (~$1B+/decade per regimen). Oncology earns average returns under low durable barriers.

Can the business be easily understood? Mostly — it is “HIV cash cow + diversification bets,” but the IPR&D-driven GAAP volatility (2024 NI $0.48B; 2026E GAAP loss) requires normalization to interpret.

Can it be undermined by foreign low-cost labor? No — IP/regulatory, not labor-cost, driven. (Generics post-LOE are the relevant low-cost threat, e.g., 2033 Biktarvy.)

Do brands matter? Physician/guideline entrenchment and prescriber relationships function as the “brand” — real switching costs, but ultimately patent- and data-backed rather than consumer-brand.

Nature of competition? Efficacy/safety/resistance and increasingly dosing convenience; payer access; guideline positioning.

Customers’ switching costs? High for virally-suppressed treatment patients (clinical rebound/resistance risk); lower for PrEP (adherence-elastic).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The HIV franchise’s intangible value (patents, lenacapavir pipeline) is internally generated and not capitalized — economic value far exceeds the ~$18/sh book.

Off-balance-sheet liabilities? Nothing material flagged; a $1.1B royalty-monetization liability is on-balance-sheet. Ordinary contingent milestone/royalty obligations from collaborations and CVRs (e.g., Arcellx $5 CVR) exist but are disclosed.

How conservative is the accounting? Reasonably conservative on its face — M&A upfronts expensed immediately as IPR&D, impairments taken promptly. The flip side: this documents ~$10B+ of capital destruction this cycle rather than hiding it.

How CapEx-hungry? Very light — capex <2% of revenue (~$0.5B), asset-light pharma.

Capital Allocation & Management

How much FCF, and how is it used? ~$9.5B FCF; ~42% to a growing dividend (~$4.0B), ~$1–2B to SBC-offsetting buybacks, the balance to serial pipeline M&A (~$11.5B upfront in 2026 alone). Philosophy: return ~60% of FCF, recycle the rest into deals.

Significant acquisitions recently? Yes — CymaBay (2024, ~$4.3B); Arcellx (closed Apr-2026, ~$7.8B); Ouro + Tubulis (2026, closing Q2); Galapagos restructuring (Mar-2026). Track record outside Pharmasset is overpayment + write-offs.

Buying back shares? Modestly — only enough to offset SBC; share count flat at ~1,255M.

Issuing large amounts of stock to insiders? SBC modest (~$0.9B, ~3% of sales — low for biopharma).

Compensation policy? (Fact — 2026 proxy.) CEO O’Day ~$28.4M (2025); low base, heavy PSU/option. Metrics: revenue, operating income, EPS growth, relative TSR — no return-on-capital metric. Say-on-pay ~91%. Combined Chair/CEO with a recurring independent-chair proposal.

Motivations of management? Form-aligned (equity-heavy) but metric-misaligned for a serial acquirer (no ROIC hurdle). Strategy is explicitly “maximize long-acting HIV + accelerate the oncology/inflammation pipeline build.”

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a US C-corporation common stock (NASDAQ: GILD); standard 1099 dividend treatment.

Dividend policy? ~$3.16/share annualized, ~2.5% yield, raised every year since 2015 initiation; ~42% FCF payout; safe.

How profitable is the business? See above — franchise extraordinarily profitable; consolidated returns diluted by M&A.

Is net income diverging from cash from operations? (Fact — yes, materially.) GAAP NI swings on non-cash IPR&D (2024 NI $0.48B vs OCF $10.8B; 2026E GAAP loss vs ~$10B OCF). Use FCF/normalized earnings, not GAAP NI.

Risks & Downside

What would cause the stock to decline? A deep 2028 Biktarvy Medicare cut; evidence lenacapavir is net-cannibalizing; further oncology failures/write-offs; broader IRA selection of HIV products; a P/S de-rate from the 95th percentile; a BIC/LEN regulatory setback.

Risk of catastrophic loss? Low — fortress balance sheet (net debt ~1.0x EBITDA), ~$9.5B FCF, diversified-enough revenue.

Chance of a total loss? Negligible — no solvency path is visible; the realistic bear is multi-year stagnation + de-rating, not impairment.

Recent News & Events

Has the business environment changed recently? Yes — positively on HIV (Yeztugo blockbuster trajectory; once-weekly oral Phase 3 win Jun-2026; BIC/LEN PDUFA Aug-2026) and negatively on oncology/policy (EVOKE-03 NSCLC failure Jun-2026; ~$11.5B unproven M&A; Biktarvy Medicare selection effective 2028; ~2% policy headwind).

Significant acquisitions? Arcellx (closed Apr-2026), Ouro + Tubulis (pending), Galapagos restructuring — see above.

Change in accounting policies? None material; IPR&D expensing is longstanding.

Recent changes — new markets, facilities, management? Leadership stable (O’Day Chairman & CEO since 2019; Dickinson CFO; Mercier CCO; Berger CMO; Perettie EVP Kite). Strategic pivot deepening into oncology/inflammation.

APPENDIX B — Source Appendix

Gilead Sciences, Inc. (NASDAQ: GILD) — Research as of 2026-06-12

Sources are primary-first. All financial figures are reconciled to SEC filings / EDGAR XBRL; management commentary is treated as a hypothesis and validated against filings and external data.

Primary — SEC filings (EDGAR, CIK 0000882095)

1. Gilead Sciences FY2025 Form 10-K, filed 2026-02-24 (gild-20251231.htm). Statements of Operations, Balance Sheet, Cash Flows; MD&A product-sales-by-geography table; Item 1 Business (Competition, Government Regulation, Patents/Exclusivity); Item 1A Risk Factors (IRA, Biktarvy Medicare selection effective 2028); Debt note; Goodwill & Intangibles; IPR&D/acquisitions notes. Mirrored locally: output/GILD/sources/10-K/.
2. Gilead 10-Q filings (FY2024–FY2026 quarters), output/GILD/sources/10-Q/.
3. Gilead Form 8-K filings (earnings, M&A, exec/board, litigation; 48 in the 5-yr corpus), output/GILD/sources/8-K/.
4. Gilead DEF 14A Proxy Statement 2026, filed 2026-03-20 (gild014721-def14a.htm): compensation structure (annual incentive 60% financial / 40% strategic; LTI 50% PSU on relative TSR + EPS / 25% options / 25% RSU); CEO O’Day SCT ($28.4M, 2025); say-on-pay ~91%; independent-chair stockholder proposal. Prior proxies 2022–2025 for trend.
5. Form 3/4/5 insider corpus (328 filings; reviewed 120 most recent): zero individual open-market purchases; 51/52 sales under Rule 10b5-1 plans. output/GILD/sources/4/.
6. EDGAR XBRL companyconcept (accessed 2026-06-12): RevenueFromContractWithCustomerExcludingAssessedTax, OperatingIncomeLoss, NetIncomeLoss, CostOfGoodsAndServicesSold, ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost, SellingGeneralAndAdministrativeExpense, Goodwill, IntangibleAssetsNetExcludingGoodwill, IndefiniteLivedIntangibleAssetsExcludingGoodwill, LongTermDebtNoncurrent, StockholdersEquity, ShareBasedCompensation, NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment, PaymentsForRepurchaseOfCommonStock, PaymentsOfDividends, WeightedAverageNumberOfDilutedSharesOutstanding.

Primary — earnings calls & investor events (mirrored: output/GILD/transcripts/)

7. Q1 2026 Earnings Call, 2026-05-07 — FY26 guidance (base business $29.4–29.8B, +5–6%; total product $30–30.4B; ex-transaction non-GAAP EPS $8.45–$8.85; GAAP loss $(1.05)–$(0.65); $11.5B IPR&D; tax 140–190%; ~2% policy headwind; non-GAAP GM ~87%, op margin ~47%, tax 18.3%); HIV +10% YoY; Biktarvy $3.4B, >52% US share; Descovy $807M (+38%); Yeztugo $166M (+72% q/q, raised to ~$1B FY26); Trodelvy +37%; cell therapy −12%; Livdelzi +200%; capital return ~60% of FCF.
8. Q4 2025 Earnings Call, 2026-02-10 — FY25 results; initial FY26 guidance.
9. Q3 2025 / Q2 2025 Earnings Calls (2025-10-30; 2025-08-07).
10. Bernstein 42nd Strategic Decisions Conference, 2026-05-28 — “no major LOE until 2036”; lenacapavir ~17-yr development; PrEP TAM 1.2M→2.2M, ~0.5M treated → >1M by mid-2030s; once-yearly IM lenacapavir target 2028; FY25 absorbed ~$1.2B Part D redesign; M&A cadence/discipline.
11. Galapagos NV / Gilead M&A Call, 2026-03-31 — collaboration restructuring around gamgertamig; ~$1.675B upfront split 50/50 + up to $500M milestones.
12. Special Call, 2026-04-07 — Arcellx / Ouro / Tubulis transaction overview.

Secondary — data feeds & news (treated as signal, validated to primary)

15. Market-data aggregator (accessed 2026-06-12) — snapshot (sector, employees, description, analyst target ~$158, rating 4.13, short interest 1.9%, institutions ~92%); valuation_index own-history percentiles (P/E 53rd, P/B 88th, P/S 95th, composite 79th).
16. Financial news aggregator (accessed 2026-06-12) — EVOKE-03/KEYNOTE-D46 discontinuation (2026-06-08/09, negative); islatravir/lenacapavir once-weekly oral Phase 3 (2026-06-08, positive); Cencora/Kite distribution (2026-06-02). Underlying company releases validated.
17. yfinance / fetch.py (2026-06-12) — price $125.07, market cap ~$155.3B, EV ~$168.5B, total debt ~$22.2B, cash ~$9.8B, 52-wk $104.46–$157.29; peer multiples (ABBV/MRK/PFE/AMGN/BMY/JNJ) recomputed.

Analytical frameworks

Analytical frameworks — Greenwald & Kahn, Competition Demystified (moat taxonomy; market-share-stability and ROIC tests; barriers-to-entry); Marathon Asset Management, Capital Returns (supply-side capital-cycle; asset-growth anomaly).